Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma

Article Link: Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma

Tibsovo is the first and only targeted therapy approved for patients with previously treated IDH1-mutated cholangiocarcinoma

BOSTON, Aug. 25, 2021 /PRNewswire/ — Servier Pharmaceuticals, a growing leader in oncology committed to bringing the…

Source: FDA New Drug Approvals